Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [11/28/2025 10:30 PST] Savara Inc. (NASDAQ:SVRA), Up By 100% ($4.67) From $4.67 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [11/21/2025 06:58 PST] SVRA Expected to Trade Up After Bullish Patterns Develop
• [11/19/2025 15:52 PST] Savara Inc. (NASDAQ:SVRA), Up By 100% ($4.12) From $4.12 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [11/13/2025 06:15 PST] sector Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.
• [10/23/2025 07:14 PDT] SVRA Expected to Trade Up After Bullish Patterns Develop
• [10/22/2025 07:21 PDT] SVRA Expected to Trade Up After Bullish Patterns Develop